PRKDC Antibody

What is PRKDC and why is it important to study with antibodies?

PRKDC (Protein Kinase, DNA-Activated, Catalytic Polypeptide) encodes DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a serine/threonine protein kinase that serves as a molecular sensor for DNA damage. It forms part of the DNA-PK complex that is crucial for DNA double-strand break repair through non-homologous end joining (NHEJ) and V(D)J recombination . Additionally, in mice, DNA-PK interacts with the transcription factor autoimmune regulator (AIRE) to promote central T-cell tolerance .

The importance of studying PRKDC with antibodies stems from its critical roles in:

• DNA damage repair mechanisms

• V(D)J recombination in developing T and B cells

• Potential contribution to central immune tolerance

• Association with immunodeficiency disorders and cancer development

• Emerging role as a biomarker and therapeutic target in immunotherapy

For researchers, antibodies against PRKDC provide essential tools to visualize, quantify, and characterize this protein in various experimental contexts.

Which applications are PRKDC antibodies most commonly used for?

Based on the available research data, PRKDC antibodies are most frequently employed in:

• Western Blotting (WB): For detecting PRKDC protein expression levels, with typical dilutions ranging from 1:500-1:4000

• Immunohistochemistry (IHC): For visualizing PRKDC localization in tissue sections (1:50-1:500 dilution)

• Immunofluorescence/Immunocytochemistry (IF/ICC): For subcellular localization studies (1:50-1:500 dilution)

• Immunoprecipitation (IP): For isolating PRKDC protein complexes (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate)

• ELISA: For quantitative detection of PRKDC protein

• Co-Immunoprecipitation (Co-IP): For studying protein-protein interactions with PRKDC

The selection of application should be guided by the specific research question and experimental design.

How do I select the appropriate PRKDC antibody for my experiment?

When selecting a PRKDC antibody, consider these critical factors:

Epitope specificity:

• Total PRKDC detection: Choose antibodies targeting conserved regions of PRKDC

• Phosphorylation-specific: Select antibodies that recognize specific phosphorylation sites (e.g., pThr2609, pSer2056)

Host species and clonality:

• Monoclonal antibodies (e.g., rabbit monoclonal clones RM505, 3H6, 1B9) offer high specificity and reproducibility

• Polyclonal antibodies provide broader epitope recognition but may have batch-to-batch variability

Validated applications:

• Confirm the antibody has been validated for your specific application (WB, IHC, IF/ICC, etc.)

• Review published literature using the antibody for similar applications

Species reactivity:

• Ensure reactivity with your species of interest (human, mouse, rat, etc.)

Control samples:

• Consider availability of positive and negative controls (e.g., M059K (DNA-PKcs positive) vs. M059J (DNA-PKcs negative) cell lines)

Always review validation data provided by manufacturers and published literature to ensure the antibody performs reliably in your experimental system.

How should I optimize Western blot protocols for PRKDC detection?

Optimizing Western blot protocols for PRKDC detection requires special considerations due to its high molecular weight (350-460 kDa):

Sample preparation:

• Use phosphatase inhibitors if detecting phosphorylated forms (e.g., pThr2609)

• Include protease inhibitors to prevent degradation

• For total cell lysates, use RIPA or NP-40 buffer with thorough homogenization

Gel electrophoresis:

• Use low percentage (3-5%) SDS-PAGE gels or gradient gels (4-12%) to properly resolve high molecular weight proteins

• Run gels at lower voltage (60-80V) for longer periods to improve resolution

• Consider using specialized high molecular weight protein ladders

Transfer conditions:

• Employ wet transfer methods rather than semi-dry for large proteins

• Use lower voltage (30V) for extended periods (overnight at 4°C)

• Add 0.1% SDS to transfer buffer to facilitate movement of large proteins

Antibody dilution and incubation:

• Primary antibody: Start with manufacturer's recommended dilution (typically 1:1000-1:4000)

• Extend primary antibody incubation (overnight at 4°C)

• Use 5% non-fat milk or BSA for blocking and antibody dilution

Detection:

• Use enhanced chemiluminescence (ECL) detection systems with longer exposure times

• Consider using more sensitive detection systems for low expression levels

Controls:

• Include positive controls (M059K cells) and negative controls (M059J cells)

• For phospho-specific antibodies, include samples treated with DNA-damaging agents and untreated controls

Optimizing these parameters will improve detection specificity and sensitivity for PRKDC in Western blot applications.

What are the best practices for immunohistochemical detection of PRKDC in tissue samples?

For optimal immunohistochemical detection of PRKDC in tissue samples:

Tissue preparation and fixation:

• Use freshly collected tissues fixed in 10% neutral buffered formalin

• Limit fixation time (24-48 hours) to preserve epitope integrity

• Paraffin embedding should follow standard protocols

• Cut sections at 4-5 μm thickness

Antigen retrieval:

• Heat-induced epitope retrieval is critical for PRKDC detection

• Use TE buffer (pH 9.0) as primary recommendation

• Alternative: citrate buffer (pH 6.0)

• Apply sufficient heating (95-100°C for 15-20 minutes)

Blocking and antibody incubation:

• Block endogenous peroxidase activity with 3% H₂O₂

• Use protein block (5% normal serum from secondary antibody host species)

• For primary antibody:

  • Dilute according to manufacturer's recommendations (typically 1:50-1:500)

  • Incubate overnight at 4°C or 1-2 hours at room temperature

  • Wash thoroughly between steps

Detection system:

• Use polymer-based detection systems for enhanced sensitivity

• Develop with DAB substrate and counterstain with hematoxylin

• Apply appropriate mounting medium

Controls and validation:

• Include positive control tissues (normal colon, breast cancer)

• Include negative controls (omit primary antibody)

• Consider comparative staining with phospho-specific antibodies in cases of DNA damage research

Special considerations:

• For cancer studies, compare normal versus tumor tissue

• For radiation/chemotherapy studies, include treated and untreated samples

• For dual staining with other markers, optimize antibody combinations to avoid cross-reactivity

These practices will enhance staining quality and interpretation of PRKDC expression in tissue samples.

How can I design experiments to study PRKDC phosphorylation after DNA damage?

Designing experiments to study PRKDC phosphorylation after DNA damage requires careful planning:

Experimental setup:

• Cell line selection:

  • Use cell lines with known PRKDC expression (e.g., HeLa, MCF-7)

  • Include PRKDC-deficient cells as negative controls (e.g., M059J)

  • Consider paired cell lines with and without PRKDC knockdown/knockout

• DNA damage induction:

  • Ionizing radiation: Typically 2-10 Gy, with time points from 15 minutes to 24 hours post-exposure

  • Chemical agents: Cisplatin (1-10 μM) , etoposide, or bleomycin at appropriate concentrations

  • Create time-course experiments to capture phosphorylation dynamics

• Phosphorylation site selection:

  • Key sites include pThr2609 and pSer2056 , each with distinct roles in DNA repair

  • Select phospho-specific antibodies validated for the sites of interest

Detection methods:

• Western blotting:

  • Use phospho-specific antibodies (e.g., anti-pThr2609)

  • Include total PRKDC antibody on parallel blots or after stripping

  • Co-detect γH2A.X as a marker of DNA damage

• Immunofluorescence:

  • Visualize phospho-PRKDC foci formation at DNA damage sites

  • Perform co-localization studies with γH2A.X or 53BP1

  • Quantify foci number and intensity over time

• Flow cytometry:

  • Analyze phospho-PRKDC levels in conjunction with cell cycle analysis

  • Correlate with other DNA damage markers

Validation approaches:

• Pharmacological inhibition:

  • Use DNA-PK inhibitors (e.g., M3814) to confirm specificity

  • Apply inhibitors before DNA damage to block phosphorylation

• Genetic manipulation:

  • Compare PRKDC knockdown/knockout cells to wild-type

  • Rescue experiments with wild-type or mutant PRKDC constructs

• Functional assays:

  • Comet assay to measure DNA damage repair capacity

  • Cell survival assays following DNA damage

  • V(D)J recombination assays in appropriate cell types

This comprehensive experimental design will enable robust analysis of PRKDC phosphorylation dynamics in response to DNA damage.

How do I interpret PRKDC phosphorylation patterns in the context of DNA damage response?

Interpreting PRKDC phosphorylation patterns requires understanding the temporal and functional significance of different phosphorylation sites:

Temporal dynamics:

• Rapid phosphorylation (within minutes) at specific sites like Thr2609 indicates early DNA damage recognition

• Sustained phosphorylation (hours) suggests ongoing DNA repair processes

• Delayed dephosphorylation may indicate impaired repair completion

Site-specific significance:

• pThr2609: Critical for DNA repair complex assembly and NHEJ efficiency

• pSer2056: Associated with autophosphorylation and kinase activation

• Multiple sites phosphorylated simultaneously indicate robust activation

Context-dependent interpretation:

• Normal cells vs. cancer cells:

  • Cancer cells may show aberrant baseline phosphorylation

  • Different tumor types show varying PRKDC phosphorylation responses

• Treatment responses:

  • Post-radiotherapy samples typically show increased phospho-PRKDC

  • Chemotherapy-treated samples may show distinct patterns compared to radiotherapy

  • PRKDC inhibitors should decrease phosphorylation at most sites

• Correlation with other markers:

  • γH2A.X correlation: Strong co-localization confirms DNA damage sites

  • 53BP1 association: Indicates pathway choice toward NHEJ

  • RAD51 absence: Confirms NHEJ rather than homologous recombination

Common challenges in interpretation:

• Non-specific bands in Western blots, particularly when detecting phospho-PRKDC

• IR-inducible signals at the same molecular weight as DNA-PKcs may represent other proteins (e.g., 53BP1)

• Variability in phosphorylation kinetics across cell types

When interpreting results, consider performing IP prior to Western blot detection to improve specificity, especially for phospho-specific detection .

What are common challenges when detecting PRKDC in Western blots and how can I overcome them?

Detecting PRKDC in Western blots presents several challenges due to its high molecular weight and specific properties:

Challenge 1: Poor protein transfer of high molecular weight PRKDC

• Solution:

  • Use wet transfer systems instead of semi-dry

  • Lower transfer voltage (30V) with extended duration (overnight at 4°C)

  • Add 0.1% SDS to transfer buffer to facilitate large protein migration

  • Consider using polyvinylidene difluoride (PVDF) membranes with 0.45 μm pore size

Challenge 2: Non-specific bands or background

• Solution:

  • Increase blocking time (2 hours at room temperature or overnight at 4°C)

  • Optimize primary antibody dilution (test range from 1:500-1:4000)

  • Extend washing steps (5-6 times, 10 minutes each)

  • Use highly specific monoclonal antibodies for cleaner results

  • Perform immunoprecipitation before Western blotting for enhanced specificity

Challenge 3: Cross-reactivity with similar sized proteins

• Solution:

  • Include appropriate controls (M059K vs. M059J cells)

  • For phospho-specific detection, be aware that 53BP1 can run at a similar size to PRKDC and may be phosphorylated in an IR-dependent manner

  • Use knockout/knockdown samples as negative controls

Challenge 4: Low signal intensity

• Solution:

  • Increase protein loading (50-100 μg per lane)

  • Enhance sensitivity using more sensitive ECL substrates

  • Extend primary antibody incubation time (overnight at 4°C)

  • Reduce washing stringency slightly (lower salt concentration)

Challenge 5: Protein degradation

• Solution:

  • Add protease inhibitor cocktail to lysis buffer

  • Keep samples on ice during preparation

  • Use freshly prepared samples when possible

  • Avoid repeated freeze-thaw cycles

Challenge 6: Inconsistent phospho-specific detection

• Solution:

  • Add phosphatase inhibitors to lysis buffer

  • Process samples quickly to minimize dephosphorylation

  • Include positive controls (irradiated cells) and negative controls

  • Validate phospho-specific signal with lambda phosphatase treatment

Implementing these solutions should improve PRKDC detection in Western blotting applications.

How do I troubleshoot negative or weak IHC staining of PRKDC in tissue samples?

When encountering negative or weak IHC staining of PRKDC in tissue samples, a systematic troubleshooting approach is essential:

1. Antigen retrieval issues:

• Problem: Insufficient antigen retrieval is a primary cause of weak staining

• Solutions:

  • Optimize buffer type (try TE buffer pH 9.0 as primary recommendation)

  • Extend retrieval time (20-30 minutes)

  • Ensure sufficient heating (95-100°C)

  • Try alternative methods: microwave, pressure cooker, or water bath

2. Fixation-related problems:

• Problem: Over-fixation or improper fixation can mask epitopes

• Solutions:

  • Use optimally fixed tissues (24-48 hours in 10% neutral buffered formalin)

  • For archived tissues, extend antigen retrieval time

  • Consider testing frozen sections which may preserve epitopes better

3. Antibody-related issues:

• Problem: Inappropriate antibody dilution or non-optimal antibody

• Solutions:

  • Test a range of antibody dilutions (start with 1:50-1:200)

  • Extend primary antibody incubation (overnight at 4°C)

  • Try different antibody clones targeting distinct epitopes

  • Verify antibody performance with positive control samples

4. Detection system limitations:

• Problem: Insufficient sensitivity of detection system

• Solutions:

  • Switch to polymer-based detection systems

  • Use amplification systems (tyramide signal amplification)

  • Extend chromogen development time

  • Ensure secondary antibody matches host species of primary antibody

5. Tissue-specific considerations:

• Problem: Variable PRKDC expression across tissues

• Solutions:

  • Include known positive control tissues (colon, breast cancer)

  • Consider tissue-specific optimization of protocols

  • For cancer tissues, compare with matched normal samples

6. Technical processing issues:

• Problem: Procedural errors during staining

• Solutions:

  • Ensure sections don't dry during the procedure

  • Maintain consistent temperature during incubations

  • Verify proper washing between steps

  • Check reagent quality and storage conditions

7. Biological interpretation challenges:

• Problem: Naturally low PRKDC expression in certain tissues

• Solutions:

  • Compare with tissues known to express PRKDC highly

  • Use super-sensitive detection methods for low-expressing tissues

  • Consider RNA-level verification (RNA-ISH or RT-PCR)

Validation approaches:

• Test multiple antibodies targeting different PRKDC epitopes

• Compare total PRKDC antibody with phospho-specific antibodies

• Include tissues from treated samples (radiation/chemotherapy) which may upregulate PRKDC

These troubleshooting steps should help resolve negative or weak PRKDC staining in tissue samples.

How can PRKDC antibodies be used to study cancer immunotherapy biomarkers?

PRKDC antibodies present valuable tools for studying cancer immunotherapy biomarkers, particularly given PRKDC's emerging role as a predictive biomarker for checkpoint blockade immunotherapy:

Biomarker discovery applications:

• Mutation status correlation:

  • Use PRKDC antibodies in conjunction with sequencing to correlate protein expression with mutation status

  • Compare antibody detection between wild-type and mutant PRKDC tumors

  • Particularly relevant as PRKDC mutations show high response rates to immunotherapy in lung cancer (75%), melanoma (53.8%), and renal cell carcinoma (50%)

• Phosphorylation status assessment:

  • Apply phospho-specific antibodies (e.g., pThr2609) to evaluate activation state

  • Compare phosphorylation patterns between responders and non-responders to immunotherapy

  • Study phosphorylation changes following treatment

• Multiplex IHC approaches:

  • Combine PRKDC antibodies with immune cell markers (CD8, PD-1, PD-L1)

  • Analyze spatial relationships between PRKDC expression and tumor-infiltrating lymphocytes

  • Create comprehensive immune contexture profiles

Experimental methodologies:

• Tissue microarray analysis:

  • Screen large cohorts of patient samples for PRKDC expression

  • Correlate with clinical outcomes and response to immunotherapy

  • Create scoring systems based on expression intensity and distribution

• Single-cell approaches:

  • Use flow cytometry with PRKDC antibodies to assess expression in different cell populations

  • Combine with other biomarkers (e.g., γH2A.X) for comprehensive cellular profiling

• Functional assays:

  • Utilize PRKDC antibodies in combination with PRKDC inhibitors (e.g., M3814)

  • Monitor DNA damage response changes in tumor and immune cells

  • Assess effects on tumor mutational burden, which correlates with PRKDC mutations

Clinical application development:

• Companion diagnostic development:

  • Standardize IHC protocols for potential clinical use

  • Establish cutoffs for positive/negative status

  • Correlate with genomic testing for PRKDC mutations

• Combination therapy assessment:

  • Monitor PRKDC expression/phosphorylation during combined checkpoint inhibitor and DNA-PK inhibitor therapy

  • Use as pharmacodynamic biomarker for drug activity

• Resistance mechanism studies:

  • Compare PRKDC expression/phosphorylation in sensitive versus resistant tumors

  • Track temporal changes during treatment and progression

Validation in animal models:

• Use PRKDC antibodies to characterize expression in models such as CT26 PRKDC-knockout mice treated with anti-PD-L1 antibodies

• Correlate with treatment response and immune infiltration

This multifaceted approach enables comprehensive investigation of PRKDC as both a biomarker and therapeutic target in cancer immunotherapy.

What is the relationship between PRKDC mutations and mutation load, and how can antibodies help investigate this?

The relationship between PRKDC mutations and mutation load is a critical area of research with implications for cancer immunotherapy. PRKDC antibodies can provide valuable insights into this relationship:

Understanding the relationship:

PRKDC mutations are significantly associated with high mutation loads across multiple cancer types, including:

• Cervical squamous cell carcinoma and endocervical adenocarcinoma

• Colon adenocarcinoma

• Head and neck squamous cell carcinoma

• Lung adenocarcinoma

• Gastric adenocarcinoma

• Endometrial cancer

Additionally, PRKDC mutations in gastric and colon cancers are highly associated with microsatellite instability-high (MSI-H) status .

Mechanisms underlying this relationship:

• Compromised DNA repair: PRKDC mutations impair DNA double-strand break repair, leading to genomic instability

• Defective V(D)J recombination: May contribute to immune dysfunction

• Increased sensitivity to DNA damage: Results in higher mutational burden when exposed to endogenous or exogenous DNA damaging agents

Antibody-based investigation strategies:

• Expression-mutation correlation studies:

  • Use PRKDC antibodies to quantify protein expression in tumors with known mutation status

  • Compare expression patterns between wild-type and various mutation types (missense, truncating, functional domain mutations)

  • Analyze whether certain mutation patterns result in distinctive protein expression profiles

• Functional impact assessment:

  • Apply phospho-specific antibodies to determine if mutations affect phosphorylation at key sites like Thr2609

  • Compare kinase activity in wild-type versus mutant PRKDC tumors

  • Evaluate downstream pathway activation

• DNA damage response visualization:

  • Use PRKDC antibodies alongside DNA damage markers (γH2A.X)

  • Quantify co-localization patterns in PRKDC-mutant versus wild-type cells

  • Assess repair kinetics following DNA damage

• Experimental models:

  • Generate cell lines with PRKDC knockdown/knockout to model mutation effects

  • Employ antibodies to validate protein loss/reduction

  • Monitor mutation accumulation over time (30+ generations)

  • Compare effects of DNA-damaging agents (radiation, cisplatin) on mutation burden

• Clinical sample analysis:

  • Perform IHC on tumor samples stratified by mutation load

  • Correlate PRKDC expression patterns with mutation load metrics

  • Investigate relationship with other genomic instability markers

Methodological approach:

This comprehensive approach using PRKDC antibodies provides mechanistic insights into how PRKDC mutations contribute to increased mutation load and potential therapeutic vulnerabilities.

How can PRKDC antibodies be used to study the role of PRKDC in immune-related disorders?

PRKDC antibodies offer powerful tools for investigating PRKDC's role in immune-related disorders, particularly given its involvement in immunodeficiency and autoimmunity:

Research applications in primary immunodeficiency:

• Diagnostic investigations:

  • Use PRKDC antibodies to assess protein expression in patients with suspected PRKDC deficiency

  • Compare expression levels between patients and healthy controls

  • Evaluate specific mutations' effects on protein expression or localization

• Functional studies in immune cells:

  • Analyze PRKDC expression in different lymphocyte subsets (T cells, B cells)

  • Monitor developmental stages of lymphocytes in relation to PRKDC expression

  • Investigate V(D)J recombination defects through PRKDC visualization

• Mechanistic investigation:

  • Study the temporal dynamics of PRKDC phosphorylation during lymphocyte development

  • Examine co-localization with recombination machinery components

  • Assess DNA repair capacity in patient-derived cells

Applications in autoimmune conditions:

Recent findings have linked PRKDC mutations to inflammatory disease with granuloma and autoimmunity . PRKDC antibodies can help investigate:

• AIRE interaction studies:

  • Co-immunoprecipitation with PRKDC antibodies to assess interaction with AIRE

  • Visualization of co-localization in medullary thymic epithelial cells (mTECs)

  • Comparison between wild-type and mutant PRKDC forms

• Central tolerance mechanisms:

  • Examine PRKDC expression in thymic tissues of patients with autoimmunity

  • Assess relationship between PRKDC expression and autoantibody production

  • Study tissue-specific antigen expression in relation to PRKDC function

• T cell repertoire analysis:

  • Correlate PRKDC expression with T cell receptor diversity

  • Investigate the presence of autoreactive T cells in relation to PRKDC dysfunction

  • Examine T cell subset distribution (TH1, TH2, TH17) in PRKDC-deficient conditions

Methodological approaches:

• Patient sample analysis:

  • Flow cytometry with PRKDC antibodies to assess expression in immune cell subsets

  • IHC of lymphoid tissues to visualize PRKDC distribution

  • Western blotting of patient-derived lymphocytes to quantify expression levels

• Functional assays:

  • Radiation sensitivity testing with subsequent PRKDC phosphorylation analysis

  • V(D)J recombination assays with PRKDC visualization

  • DNA repair kinetics assessment using PRKDC and γH2A.X antibodies

• Animal model validation:

  • Characterize PRKDC expression in mouse models of immunodeficiency

  • Compare with human samples to validate translational relevance

  • Assess effects of PRKDC restoration on immune function

Case study approach:

The investigation of patients with PRKDC mutations presenting with immunodeficiency and autoimmunity revealed:

• Progressive T- and B-cell deficiency

• Granulomas and various autoantibodies

• Oligoclonal T-cell repertoire

• Immune dysregulation with shift to TH1 and TH2, but not TH17 lymphocytes

• Defect in AIRE transcriptional activity

• APECED-related autoantibody production

Using PRKDC antibodies to characterize protein expression and localization in these cases can provide critical insights into disease mechanisms and potential therapeutic approaches.

What are the considerations when using PRKDC antibodies to evaluate DNA-PK inhibitors in cancer therapy?

Using PRKDC antibodies to evaluate DNA-PK inhibitors requires careful consideration of several factors to ensure meaningful and interpretable results:

Experimental design considerations:

Pharmacodynamic marker assessment:

• Direct target engagement:

  • Monitor phosphorylation status of PRKDC itself

  • Track autophosphorylation sites (indicative of kinase activity)

  • Assess dose-dependent inhibition profiles

• Downstream signaling effects:

  • Evaluate DNA damage persistence (γH2A.X levels)

  • Monitor repair protein recruitment to damage sites

  • Assess cell cycle checkpoint activation

• Functional outcomes:

  • Measure DNA repair capacity (comet assay)

  • Evaluate cell survival following DNA damage

  • Quantify mutagenesis rates

Immunotherapy combination approaches:

When evaluating DNA-PK inhibitors in combination with immunotherapy (as supported by research findings ), consider:

• Sequencing effects:

  • DNA-PK inhibitor before, during, or after checkpoint blockade

  • Effect on mutation load and neoantigen presentation

  • Impact on immune cell recruitment and function

• Therapeutic synergy assessment:

  • Compare DNA-PK inhibitor alone, immunotherapy alone, and combination

  • Evaluate potential antagonistic effects

  • Monitor for increased toxicity (body weight changes)

• Biomarker development:

  • PRKDC expression/phosphorylation as predictive biomarkers

  • On-treatment biopsies to confirm target modulation

  • Correlation with clinical outcomes

Protocol example from research findings:

Technical considerations:

• Timing of sample collection:

  • Immediate (1-2 hours) for phosphorylation changes

  • Intermediate (24-48 hours) for downstream effects

  • Long-term (weeks) for tumor response

• Sample processing:

  • Rapid fixation/freezing to preserve phosphorylation status

  • Consistent protocols across treatment groups

  • Appropriate controls for each experiment

• Quantification methods:

  • Digital image analysis for IHC/IF

  • Densitometry for Western blots

  • Flow cytometry for cellular analyses

These considerations enable rigorous evaluation of DNA-PK inhibitors as both monotherapy and in combination with immunotherapy, particularly important given PRKDC's emerging role as both a biomarker and therapeutic target in cancer.

How might PRKDC antibodies contribute to understanding the relationship between DNA repair and immune checkpoint inhibitor response?

PRKDC antibodies offer critical tools for investigating the mechanistic link between DNA repair deficiency and immune checkpoint inhibitor response:

Conceptual framework:

The relationship between PRKDC dysfunction and immunotherapy response appears to involve:

• Increased mutation load due to impaired DNA repair

• Enhanced neoantigen production and presentation

• Greater immunogenicity of tumors

• Improved recognition by activated T cells following checkpoint blockade

Investigative approaches using PRKDC antibodies:

• DNA damage-immune activation interface:

  • Use PRKDC and γH2A.X antibodies to visualize DNA damage foci

  • Correlate with immune cell infiltration markers in multiplex IHC

  • Compare patterns in responders versus non-responders to immunotherapy

• Mutation accumulation dynamics:

  • Apply PRKDC antibodies to validate knockdown/knockout models

  • Track mutation accumulation over time using sequencing

  • Correlate with neoantigen load and immune recognition

• Mechanistic studies in preclinical models:

  • CT26 tumor models with PRKDC knockout showed enhanced response to anti-PD-L1 therapy

  • Use antibodies to confirm PRKDC status in these models

  • Apply phospho-specific antibodies to track DNA repair kinetics

• Clinical sample analysis:

  • Stratify patient samples by PRKDC mutation status and expression patterns

  • Correlate with response to immunotherapy

  • Develop predictive biomarker panels combining PRKDC status with immune markers

Experimental design table:

Translational implications:

• Biomarker development:

  • PRKDC mutation status has potential as a predictive biomarker

  • Antibody-based assays could provide rapid screening compared to sequencing

  • IHC patterns might supplement or substitute for genetic testing in some contexts

• Therapeutic combinations:

  • DNA-PK inhibitors enhanced anti-PD-L1 efficacy in preclinical models

  • PRKDC antibodies can monitor pharmacodynamic effects of inhibitors

  • Guide optimal timing and dosing of combination therapies

• Resistance mechanisms:

  • Monitor changes in PRKDC expression/phosphorylation during treatment

  • Identify adaptive responses that may confer resistance

  • Guide sequential therapy approaches

This research direction has significant potential to advance personalized immunotherapy by identifying patients most likely to benefit from checkpoint inhibitors and developing rational combination strategies.

What role might PRKDC antibodies play in studying radiation and chemotherapy resistance mechanisms?

PRKDC antibodies provide essential tools for investigating radiation and chemotherapy resistance mechanisms, given the central role of DNA-PKcs in DNA damage repair:

Fundamental mechanisms of therapy resistance:

• Enhanced DNA repair capacity:

  • Upregulated PRKDC expression in resistant tumors

  • Increased phosphorylation/activation following DNA damage

  • More efficient double-strand break resolution

• Altered DNA damage response signaling:

  • Modified phosphorylation patterns at key PRKDC sites

  • Aberrant interaction with other repair proteins

  • Compensatory pathway activation

• Cellular adaptation mechanisms:

  • Selection for cells with higher PRKDC expression

  • Mutational changes affecting inhibitor binding

  • Altered subcellular localization

PRKDC antibody applications in resistance studies:

• Expression profiling in resistant models:

  • Compare PRKDC levels between sensitive and resistant cell lines/tumors

  • Track expression changes during acquisition of resistance

  • Correlate with clinical outcomes in patient samples

• Phosphorylation dynamics:

  • Monitor site-specific phosphorylation (pThr2609, pSer2056) before and after treatment

  • Compare phosphorylation kinetics in sensitive versus resistant cells

  • Identify altered phosphorylation sites associated with resistance

• Subcellular localization studies:

  • Visualize PRKDC distribution using immunofluorescence

  • Assess nuclear localization efficiency in resistant cells

  • Examine co-localization with DNA damage foci

• Protein-protein interactions:

  • Use PRKDC antibodies for co-immunoprecipitation studies

  • Identify altered interaction partners in resistant cells

  • Investigate changes in DNA repair complex formation

Experimental models and approaches:

• Isogenic resistant cell models:

  • Generate radiation/chemotherapy-resistant cell lines

  • Compare PRKDC expression, phosphorylation, and function

  • Validate findings with PRKDC knockdown/overexpression

• Patient-derived models:

  • Analyze paired samples from before treatment and after resistance

  • Correlate PRKDC patterns with treatment outcomes

  • Develop predictive signatures of resistance

• In vivo resistance models:

  • IHC analysis of PRKDC in resistant tumors

  • Compare treatment-naïve versus post-treatment samples

  • Validate findings from lung cancer with radiotherapy, chemotherapy-treated tissues

Clinical applications:

• Predictive biomarkers for therapy response:

  • Baseline PRKDC expression may predict initial sensitivity

  • Phosphorylation patterns might indicate repair capacity

  • Expression changes during treatment could signal emerging resistance

• Therapeutic targeting to overcome resistance:

  • DNA-PK inhibitors may sensitize resistant tumors

  • PRKDC antibodies can monitor inhibitor efficacy

  • Guide combination strategies with conventional therapies

• Treatment monitoring:

  • Serial biopsies to track PRKDC changes during therapy

  • Liquid biopsy approaches for circulating tumor cells

  • Correlation with imaging and clinical response

This research area has significant potential to improve outcomes for patients receiving radiation and chemotherapy by identifying resistance mechanisms early and developing targeted strategies to overcome them.

How can PRKDC antibodies contribute to understanding and treating rare immunodeficiency disorders?

PRKDC antibodies provide valuable tools for understanding and potentially treating rare immunodeficiency disorders associated with PRKDC mutations:

Clinical context of PRKDC-related immunodeficiencies:

PRKDC mutations have been associated with diverse immunological phenotypes:

• Classic SCID (Severe Combined Immunodeficiency) with T-B-NK+ phenotype

• Combined immunodeficiency with autoimmunity and granulomas

• Progressive T- and B-cell deficiency with autoantibody production

Diagnostic applications of PRKDC antibodies:

• Expression analysis in patient samples:

  • Quantify PRKDC protein levels in peripheral blood lymphocytes

  • Compare expression across different immune cell subsets

  • Correlate protein levels with specific mutations

• Functional assessment:

  • Evaluate phosphorylation at key sites (pThr2609) following DNA damage

  • Assess DNA repair capacity in patient cells

  • Analyze V(D)J recombination efficiency

• Tissue-specific investigations:

  • Examine PRKDC expression in lymphoid tissues (thymus, lymph nodes)

  • Study expression in medullary thymic epithelial cells (mTECs)

  • Investigate central versus peripheral tolerance mechanisms

Research applications for disease mechanisms:

• AIRE interaction studies:

  • Use co-immunoprecipitation with PRKDC antibodies to study AIRE interaction

  • Investigate how mutations affect this interaction

  • Examine consequences for central tolerance

• Autoimmunity development:

  • Study relationship between PRKDC expression and autoantibody production

  • Investigate T cell repertoire selection

  • Examine T cell subset distribution (TH1, TH2, TH17)

• Granuloma formation mechanisms:

  • Analyze PRKDC expression in granulomatous lesions

  • Investigate relationship with inflammatory cytokine production

  • Study macrophage activation patterns

Therapeutic development opportunities:

• Gene therapy approaches:

  • Use PRKDC antibodies to validate gene correction in patient cells

  • Monitor restored protein expression following gene therapy

  • Assess functional recovery of DNA repair and V(D)J recombination

• Small molecule interventions:

  • For gain-of-function mutations, monitor inhibition efficacy

  • For loss-of-function mutations, evaluate protein stabilizers

  • Track changes in downstream signaling pathways

• Cellular therapy monitoring:

  • Assess PRKDC expression in donor cells for transplantation

  • Monitor engraftment and immune reconstitution

  • Evaluate development of donor-derived immune cells

Experimental design considerations:

When studying rare PRKDC-related immunodeficiencies, researchers should:

This comprehensive approach using PRKDC antibodies can advance understanding of these rare disorders and potentially lead to targeted therapeutic interventions.

What are the most reliable PRKDC antibody applications based on current research?

Based on the available research data, the following PRKDC antibody applications demonstrate the highest reliability and utility:

Highly reliable applications:

• Western blotting for total PRKDC:

  • Consistently detects the expected 350-460 kDa band

  • Well-validated in multiple cell types (HeLa, MCF-7)

  • Clear differentiation between positive (M059K) and negative (M059J) controls

  • Optimal dilution range: 1:1000-1:4000

• Immunohistochemistry in FFPE tissues:

  • Successfully applied in various tissue types (colon, breast, lung)

  • Demonstrates nuclear localization as expected

  • Effective with antigen retrieval (TE buffer pH 9.0)

  • Useful for comparing normal versus tumor tissue

• Phospho-specific detection:

  • pThr2609 antibodies reliably detect DNA damage-induced phosphorylation

  • Phospho-antibodies provide functional information beyond mere presence

  • Critical for monitoring DNA-PK activation status

• Validation of genetic manipulation:

  • Confirming PRKDC knockdown/knockout in experimental models

  • Monitoring expression changes in transfected cell systems

  • Validating CRISPR-edited cell lines

Moderately reliable applications:

• Immunoprecipitation:

  • Effective for enhancing Western blot specificity

  • Useful for protein complex isolation

  • Requires optimization for each experimental system

• Immunofluorescence/ICC:

  • Visualizes subcellular localization

  • Can detect formation of damage-induced foci

  • May require signal amplification for low expression

• Co-immunoprecipitation:

  • Documented success in protein interaction studies

  • Valuable for mechanistic investigations

  • Technically challenging due to protein size

Applications requiring careful optimization:

• Flow cytometry:

  • Limited validation in published literature

  • Challenges with intracellular staining of large proteins

  • May require specialized fixation/permeabilization

• Chromatin immunoprecipitation:

  • Few validated protocols available

  • Technical challenges due to protein size

  • Requires careful control selection

Application-specific reliability factors:

This assessment of reliability can guide researchers in selecting the most appropriate PRKDC antibody applications for their specific research questions while anticipating potential technical challenges.

What emerging technologies might enhance PRKDC antibody applications in future research?

Several emerging technologies show promise for enhancing PRKDC antibody applications in future research:

1. Advanced imaging technologies:

• Super-resolution microscopy:

  • Visualize PRKDC with nanometer precision at DNA damage sites

  • Track PRKDC recruitment and dissociation kinetics in real-time

  • Resolve individual repair complexes beyond diffraction limit

• Live-cell imaging with antibody fragments:

  • Use Fab fragments or nanobodies for intracellular tracking

  • Monitor PRKDC dynamics during DNA damage response

  • Visualize interactions with repair partners in living cells

• Correlative light and electron microscopy (CLEM):

  • Combine PRKDC antibody labeling with ultrastructural analysis

  • Examine chromatin context of PRKDC recruitment

  • Visualize repair complex architecture at nanoscale resolution

2. Single-cell analysis technologies:

• Mass cytometry (CyTOF):

  • Multiplex PRKDC antibodies with dozens of other markers

  • Profile heterogeneity in DNA repair capacity across cell populations

  • Correlate PRKDC expression with cell state and lineage markers

• Single-cell Western blotting:

  • Analyze PRKDC expression in individual cells

  • Identify rare subpopulations with altered expression

  • Link to functional single-cell assays

• Spatial proteomics:

  • Map PRKDC distribution across tissue microenvironments

  • Correlate with cell types and pathological features

  • Generate spatial expression atlases in health and disease

3. Antibody engineering and modification:

• Bispecific antibodies:

  • Target PRKDC alongside other repair proteins

  • Visualize protein-protein interactions directly

  • Study pathway crosstalk in intact cells

• Proximity labeling antibodies:

  • Conjugate PRKDC antibodies with enzymes like APEX2 or TurboID

  • Identify proteins in the vicinity of PRKDC

  • Map local interactome at DNA damage sites

• Cell-penetrating antibodies:

  • Develop membrane-permeable PRKDC antibodies

  • Enable live-cell functional studies

  • Potentially disrupt specific interactions as research tools

4. High-throughput and multiplexed approaches:

• Antibody-based proteomics arrays:

  • Profile PRKDC and repair pathway components across sample cohorts

  • Integrate with genomic and transcriptomic data

  • Identify novel PRKDC interaction networks

• Digital spatial profiling:

  • Analyze PRKDC expression with spatial context

  • Multiplex with dozens of other markers

  • Preserve tissue architecture while obtaining quantitative data

• Microfluidic antibody-based assays:

  • Develop high-sensitivity PRKDC detection from limited samples

  • Enable longitudinal monitoring from patient biopsies

  • Automate and standardize detection protocols

5. Computational and AI-enhanced analysis:

• Machine learning for image analysis:

  • Automated quantification of PRKDC staining patterns

  • Classification of expression patterns with prognostic value

  • Detection of subtle changes in subcellular localization

• Integrative multi-omics platforms:

  • Correlate PRKDC antibody data with genomics, transcriptomics, and metabolomics

  • Generate comprehensive pathway models

  • Predict therapeutic vulnerabilities

These emerging technologies have the potential to significantly advance PRKDC research by providing more precise, comprehensive, and contextual information about its expression, function, and interactions in normal and pathological conditions.

What are key considerations for validating new PRKDC antibodies for research applications?

Validating new PRKDC antibodies requires a comprehensive approach to ensure specificity, sensitivity, and reproducibility across applications:

1. Epitope characterization and antibody properties:

• Epitope mapping:

  • Identify the specific region or amino acid sequence recognized

  • Determine if the epitope is in a functional domain (kinase domain, regulatory regions)

  • Assess conservation across species for cross-reactivity potential

• Antibody characteristics:

  • Document host species, clonality (monoclonal vs. polyclonal)

  • For monoclonals, specify clone designation and isotype

  • For polyclonals, document immunization protocol and purification method

• Phospho-specificity validation:

  • For phospho-specific antibodies, confirm exclusive recognition of phosphorylated form

  • Use phosphatase treatment to demonstrate specificity

  • Compare with total PRKDC antibodies in parallel experiments

2. Expression system validation:

• Positive and negative controls:

  • Use cell lines with known PRKDC expression (e.g., M059K versus M059J)

  • Include PRKDC knockdown/knockout models

  • Test against recombinant PRKDC fragments when available

• Genetic manipulation:

  • Validate using overexpression systems

  • Confirm specificity with siRNA/shRNA knockdown

  • Test with CRISPR-Cas9 edited cell lines

• Multi-species reactivity:

  • Test across relevant species (human, mouse, rat)

  • Document species-specific differences in recognition

  • Validate in transgenic/knockout animal tissues

3. Application-specific validation:

• Western blot validation:

  • Confirm single band at expected molecular weight (350-460 kDa)

  • Test different lysis conditions and sample preparation methods

  • Validate in multiple cell types and tissue lysates

• Immunohistochemistry validation:

  • Test multiple antigen retrieval methods (TE buffer pH 9.0, citrate buffer pH 6.0)

  • Optimize antibody concentration across tissue types

  • Compare with known expression patterns in tissues

• Immunofluorescence validation:

  • Confirm expected subcellular localization (primarily nuclear)

  • Test different fixation/permeabilization methods

  • Validate co-localization with known interacting partners

• Immunoprecipitation validation:

  • Confirm ability to immunoprecipitate native PRKDC

  • Verify by Western blot of immunoprecipitated material

  • Compare efficiency across buffer conditions

4. Functional validation:

• DNA damage response:

  • Test antibody detection before and after DNA damage induction

  • For phospho-specific antibodies, confirm increased signal after damage

  • Correlate with other DNA damage markers (γH2A.X)

• Inhibitor response:

  • Verify changes in phospho-specific signals with DNA-PK inhibitors

  • Document time and dose-dependent effects

  • Compare with functional readouts of DNA-PK activity

• Physiological relevance:

  • Validate in tissue samples from relevant pathologies

  • Compare normal versus cancer tissues

  • Assess treatment-related changes (radiation, chemotherapy)

5. Reproducibility assessment:

• Inter-laboratory validation:

  • Test in multiple independent laboratories

  • Document protocol differences that affect performance

  • Establish reproducibility across different equipment/settings

• Lot-to-lot consistency:

  • Compare multiple antibody lots

  • Document any variations in performance

  • Establish quality control parameters

• Protocol standardization:

  • Develop detailed protocols for each application

  • Document critical steps and potential pitfalls

  • Establish optimal conditions for reproducible results